0001628280-23-039562.txt : 20231120 0001628280-23-039562.hdr.sgml : 20231120 20231120070529 ACCESSION NUMBER: 0001628280-23-039562 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231120 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231120 DATE AS OF CHANGE: 20231120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: C4 Therapeutics, Inc. CENTRAL INDEX KEY: 0001662579 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 475617627 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39567 FILM NUMBER: 231420697 BUSINESS ADDRESS: STREET 1: 490 ARSENAL WAY STREET 2: SUITE 120 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (617) 231-0700 MAIL ADDRESS: STREET 1: 490 ARSENAL WAY STREET 2: SUITE 120 CITY: WATERTOWN STATE: MA ZIP: 02472 8-K 1 cccc-20231120.htm 8-K cccc-20231120
0001662579false00016625792023-11-202023-11-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________________
FORM 8-K
_________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 20, 2023
_________________________________________________________________
C4 THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
_________________________________________________________________
Delaware001-3956747-5617627
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
490 Arsenal Way,   Suite 120
Watertown,  MA
02472
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (617231-0700
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per shareCCCCThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
 



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 16, 2023, the Board of Directors (the “Board”) of C4 Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Owen P. Hughes, Jr. as a director of the Company. At the time of his appointment, it was not determined which board committees Mr. Hughes would sit on.
Mr. Hughes has been designated as a Class I director, to serve until the Company’s 2024 Annual Meeting of Stockholders, in accordance with the Company’s Second Amended and Restated By-Laws and to serve thereafter until his successor has been duly elected and qualified or until his earlier death, removal or resignation.
In connection with his appointment and in accordance with the Company’s compensation policy for non-employee directors, the Company granted to Mr. Hughes stock options to purchase up to 52,000 shares of the Company’s common stock under the Company’s 2020 Stock Option and Incentive Plan. One-third of this stock option award shall vest on the first anniversary of the date of grant, with the remainder vesting quarterly over the subsequent two years, provided, however, that all vesting of this award shall cease if Mr. Hughes resigns from the Board or otherwise ceases to serve as a director of the Company or otherwise maintain a service relationship with the Company prior to any such vesting date. In addition, in connection with his election, the Company is entering into an indemnification agreement with Mr. Hughes in the same form as used with the Company’s other directors.
There are no arrangements or understandings between Mr. Hughes and any other persons pursuant to which he was selected as a director of the Company, and there are no transactions in which Mr. Hughes has an interest requiring disclosure under Item 404(a) of Regulation S-K.
Item 7.01 Regulation FD Disclosure.
On November 20, 2023, the Company issued a press release announcing Mr. Hughes’ appointment to the Board. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.
Exhibit
Number
Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
C4 Therapeutics, Inc.
Date: November 20, 2023
By:/s/ Kendra R. Adams
Kendra R. Adams
Chief Financial Officer and Treasurer

EX-101.SCH 2 cccc-20231120.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 cccc-20231120_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 4 cccc-20231120_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-99.1 5 cccc-20231120xexx991.htm EX-99.1 Document

Exhibit 99.1
c4tlogo1.jpg

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the Board of Directors
WATERTOWN, Mass., November 20, 2023 (GLOBE NEWSWIRE) – C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Owen Hughes to its board of directors. Mr. Hughes is an accomplished life sciences executive with nearly three decades of experience in investing, operations and corporate governance.
“We are thrilled to welcome Owen to the board of directors and leverage his experience across capital markets and pivotal business development opportunities,” said Bruce Downey, chairman of the board of directors of C4 Therapeutics. “His knowledge will help C4 Therapeutics strategically advance our portfolio of novel degrader medicines that have the potential to transform how disease is treated.”
Mr. Hughes most recently served as co-founder and chief executive officer of Cullinan Oncology, where he led the development of the company’s portfolio of oncology assets through proof-of-concept. Under Mr. Hughes’s leadership, Cullinan raised over $400 million in capital through its initial public offering and advanced several assets into the clinic. Mr. Hughes also served as chief business officer of Intarcia Therapeutics, where he raised over $1.4 billion in capital and completed several portfolio deals totaling more than $1 billion.
Mr. Hughes started his career on Wall Street, initially in investment banking and equity research before transitioning to the buyside, where he managed public and private healthcare investments for Brookside Capital, a hedge fund under the Bain Capital umbrella, and Pyramis Advisors, a Fidelity Investments company.
Mr. Hughes currently serves as the executive chairman of Sail Bio and XOMA Corporation as well as the chairman of Ikena Oncology. He previously served on the boards of Radius Health (acquired by Gurnet Point Capital) and Translate Bio (acquired by Sanofi). Mr. Hughes earned a B.A. in history from Dartmouth College.
“It is a privilege to join C4T’s board and help advance targeted protein degradation in hopes it may offer patients and physicians a new therapeutic option,” said Mr. Hughes. “I look forward to working with the board of directors and management team to capitalize on the company’s scientific prowess to the benefit of patients and shareholders alike.”
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the



clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit www.c4therapeutics.com.
Forward-Looking Statements
This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization related to clinical trials and other clinical development activities including clinical trial commencement; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that sufficient capital to fund our future operations will be available to us on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.

Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com

GRAPHIC 6 c4tlogo1.jpg begin 644 c4tlogo1.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover Page Document
Nov. 20, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 20, 2023
Entity Registrant Name C4 THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39567
Entity Tax Identification Number 47-5617627
Entity Address, Address Line One 490 Arsenal Way,
Entity Address, Address Line Two Suite 120
Entity Address, City or Town Watertown,
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code 617
Local Phone Number 231-0700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol CCCC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001662579
Amendment Flag false
XML 8 cccc-20231120_htm.xml IDEA: XBRL DOCUMENT 0001662579 2023-11-20 2023-11-20 0001662579 false 8-K 2023-11-20 C4 THERAPEUTICS, INC. DE 001-39567 47-5617627 490 Arsenal Way, Suite 120 Watertown, MA 02472 617 231-0700 false false false false Common Stock, $0.0001 par value per share CCCC NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " "N.'1799!YDAD! #/ P $P @ &T L$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #^$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Document Sheet http://c4therapeutics.com/role/CoverPageDocument Cover Page Document Cover 1 false false All Reports Book All Reports cccc-20231120.htm cccc-20231120.xsd cccc-20231120_lab.xml cccc-20231120_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cccc-20231120.htm": { "nsprefix": "cccc", "nsuri": "http://c4therapeutics.com/20231120", "dts": { "inline": { "local": [ "cccc-20231120.htm" ] }, "schema": { "local": [ "cccc-20231120.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "cccc-20231120_lab.xml" ] }, "presentationLink": { "local": [ "cccc-20231120_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://c4therapeutics.com/role/CoverPageDocument", "longName": "0000001 - Document - Cover Page Document", "shortName": "Cover Page Document", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cccc-20231120.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cccc-20231120.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://c4therapeutics.com/role/CoverPageDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001628280-23-039562-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-039562-xbrl.zip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end